N. Meningitidis Carriage Study
NCT01808365 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2018-03-09
Summary
This carriage study aims to evaluate the presence of meningococcus in Asian populations (and potential for disease) and explore the extent and serogroup distribution of meningococci circulating in the population.
Conditions
- Infections, Meningococcal
Interventions
- PROCEDURE
-
Posterior pharyngeal swab
Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
- OTHER
-
Data collection
Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Min Age
- 5 Years
- Max Age
- 24 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-08-02
- Primary Completion
- 2014-03-25
- Completion
- 2014-03-25
Countries
- Philippines
Study Locations
More Related Trials
-
Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years
NCT00290329 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
NCT00196963 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
NCT00310635 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years
NCT01235975 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older
NCT01705379 ·Status: WITHDRAWN
-
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
NCT01641042 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
NCT01165242 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age
NCT03652610 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT02878291 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
NCT01018732 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India
NCT01086969 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
NCT00126945 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years
NCT00196950 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612
NCT00974363 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.
NCT02305446 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
NCT05252715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
NCT01482052 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
NCT01547715 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
NCT04318548 ·Status: COMPLETED ·Phase: PHASE3
-
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults
NCT00453986 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
NCT01732627 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
NCT02531698 ·Status: COMPLETED ·Phase: PHASE2
-
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine
NCT02481232 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan
NCT01410474 ·Status: COMPLETED ·Phase: PHASE3
-
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
NCT03493919 ·Status: COMPLETED ·Phase: PHASE4